Eris Lifesciences gets nod to hike foreign investors’ limit to 49%

23 Aug 2017 Evaluate

Eris Lifesciences has received an approval from Reserve Bank of India (RBI) to raise foreign investors’ stake in the company to 49%. RBI notified that Foreign Institutional Investors (FIIs)/Foreign Portfolios Investors (FPIs) investment limit under Portfolio Investment Scheme (PIS) in the company has increased from 24% to 49% of its paid up capital. Also, the NRI investment limit under PIS in the company has increased from 10% to 24%.

Eris Lifesciences is engaged in manufacturing, marketing and selling of branded generics within the chronic and acute categories of the Indian Pharmaceutical Market.


Eris Lifesciences Share Price

1389.70 -22.85 (-1.62%)
18-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1800.30
Dr. Reddys Lab 1275.05
Cipla 1472.05
Lupin 2098.70
Zydus Lifesciences 979.10
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.